Riskpilot← Back to searchSign inGet full accessPharmfab AB
ABActiveOrg 5568028780Economic activity was not specified by tax authority · NACE 0000Est. 20100 employees
Revenue 2024
SEK 0
EBITDA margin
—
-151% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -16K
+99% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | -151% |
| Net profit | SEK -16K | +99% |
| Total assets | SEK 69,5M | +0% |
| Equity | SEK 69,5M | +0% |
| Employees | 0 | — |
Legal name
Pharmfab AB
Org number
5568028780
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
29 mars 2010
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har som föremål för sin verksamhet att förvalta aktier i bolag som bedriver apoteksverksamhet samt att, direkt eller indirekt, äga och förvalta övrig fast och lös egendom och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | — | — | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −44 | −1 | −17 | 31 | −16 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −44 | −1 | −17 | 31 | −16 |
| Net financials | 1 500 | — | — | −1 500 | — |
| Profit before tax | 1 456 | −1 | −17 | −1 469 | −16 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | 1 456 | −1 | −17 | −1 469 | −16 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 71 019 | 71 010 | 71 005 | 69 504 | 69 488 |
| Equity | 70 976 | 70 975 | 70 958 | 69 489 | 69 473 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 43 | 35 | 47 | 15 | 15 |
| Total debt | 43 | 35 | 47 | 15 | 15 |
EBITDA margin
-1590100.0%
This company
15.8%
Market median
-10064024% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
-1590100.0%
This company
8.1%
Market median
-19630964% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GM Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmfab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gustav Martin Johansson | Chief Auditor | 0 companies |
| Mats Tony Christian Jansson | Deputy Board Member | 0 companies |
| Mats Mikael Winterfeldt | Board of Directors | 0 companies |